These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 700946)

  • 1. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency.
    Pietrek J; Kokot F; Kuska J
    Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
    Peacock M; Aaron JE; Walker GS; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
    Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 1alpha-hydroxyvitamin D3 on parathyroid function in patients with chronic renal failure.
    Nielsen HE; Christensen MS; Melsen F; Rømer FK; Hansen HE
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():67s-72s. PubMed ID: 606427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
    Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Nielsen PK; Egsmose C; Storm T; Olgaard K
    Am J Nephrol; 1992; 12(5):311-8. PubMed ID: 1488999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alfacalcidol in the therapy of renal bone disease.
    Ritzerfeld M; Klasser M; Mann H
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):546-50. PubMed ID: 11770836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol].
    Switalski M; Kuriga M; Wańkowicz Z
    Pol Arch Med Wewn; 1997 Oct; 98(10):358-65. PubMed ID: 9557090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients.
    Lindholm TS; Sevastikoglou JA; Lindgren U
    Clin Orthop Relat Res; 1978 Sep; (135):226-31. PubMed ID: 709935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperparathyroidism in chronic renal failure.
    Papapoulos SE; Brownjohn AM; Junor BJ; Marsh FP; Goodwin FJ; Hately W; Lewin IG; Tomlinson S; Hendy GN; O'Riordan JL
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():59s-65s. PubMed ID: 606426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
    Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
    Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.